2,986
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis

ORCID Icon, , , , ORCID Icon, , , ORCID Icon, , , , , ORCID Icon, & ORCID Icon show all
Pages 941-953 | Received 22 Dec 2021, Accepted 05 Apr 2022, Published online: 25 Apr 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Gemma Camiña-Conforto, Laura Mateu-Arrom, Anna López-Ferrer & Lluís Puig. (2023) Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives. Patient Preference and Adherence 17, pages 1541-1549.
Read now

Articles from other publishers (2)

Sonali Batta, Ramlah Khan, Marcus Zaayman, Allison Limmer, Dario Kivelevitch & Alan Menter. (2023) IL-17 and -23 Inhibitors for the Treatment of Psoriasis. EMJ Allergy & Immunology.
Crossref
Néboa Zozaya, Maria Iciar Arrizubieta Basterrechea, Elena Bollo, Iván Castellví, Jaime Espín, Norberto Ortego, José Luis Poveda-Andrés, José Antonio Rodríguez Portal, Agustín Rivero, José Antonio Marcos-Rodríguez & Luis Verde. (2022) A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases. International Journal of Technology Assessment in Health Care 38:1.
Crossref